ONCOINVENT ASA
Sector unknown·ONCIN · Oslo Børs·Fiscal year to 31/12/2024
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
Buying contract manufacturing and research (CMO/CRO/EMS)
Raw materials and inputs
InputNegative impact: weakens
“Research and development While the research and development strategy is designed in-house in BerGenBio, the Group leverages its network of external contract research organizations (CROs) in order to execute its development strategy. BerGenBio also collaborates with academic institutions to extend the research in areas of interest of the Group.”
Annual report 2024A · The company itself
InputNegative impact: weakens
“We rely on third parties for conduct of our clinical studies (Contract Research Organizations), supply of medicinal products, office supplies and housekeeping services. By end of 2024 we had 4 key suppliers.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“While the research and development strategy is designed in-house, the Company leverages our network of external contract research organizations (CROs) to execute our development strategy. BerGenBio also collaborates with academic institutions to extend research in areas of interest for the Company.”
Annual report 2024A · The company itself
Chains in: Biotech and drug development strengthens
M&A and consolidation
Macro
DriverNegative impact: weakens
“The Group operates in a highly competitive industry sector with many large players and may be subject to rapid and substantial technological change.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“Over the years, by engaging in partnerships with industry leaders, academic institutions, pharmaceutical companies and clinical research organizations, we have strategically focused our capabilities and impact. This has made us able to accelerate our innovation-driven research and development efforts.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“Following the announcement of the discontinuation of the BGBC016 clinical trial in February 2025, the Company has initiated exploration of potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, sale of assets, licensing, or other transactions. A solvent liquidation can also be an alternative.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“Consequently, the company decided to discontinue the BGBC016 study. The Board of Directors has now initiated an exploration of strategic alternatives. As part of this process, the board is considering a range of options for the company including, among other things, a potential sale, merger, or other strategic transaction.”
Annual report 2024A · The company itself
Biotech and drug development
Technology
Market
“The Group’s lead product candidate, bemcentinib, is currently in a Ph1b/2a Investigator Led clinical trial.”
Annual report 2024A · The company itself
Market
“Our vision is to improve and save lives and thereby generate a positive impact for patients, society and shareholders through our work in discovering and developing novel medicines to treat aggressive diseases, including advanced, treatment-resistant cancers.”
Annual report 2024A · The company itself
Chains in: US drug pricing policy mixed effect, Patent expiry and generic competition weakens, Drug approvals strengthens
Chains out: this strengthens Buying contract manufacturing and research (CMO/CRO/EMS), strengthens Contract manufacturers as a business (EMS, CMO, CRO)
AI regulation
Regulation
StrategyPositive impact: strengthens
“The topics which are of most strategic importance to us are; innovation, clinical trial conduct, business ethics, economic performance and patient health and safety.”
Annual report 2024A · The company itself
ESG and sustainability reporting
Regulation
StrategyPositive impact: strengthens
“The topics which are of most strategic importance to us are; innovation, clinical trial conduct, business ethics, economic performance and patient health and safety.”
Annual report 2024A · The company itself
Healthcare and hospitals
End markets
Market
“Cancer remains one of the most pressing healthcare challenges, accounting for the second most common cause of death globally. Our vision is to improve and save lives and thereby generate a positive impact for patients, society and shareholders through our work in discovering and developing novel medicines to treat aggressive diseases, including advanced, treatment-resistant cancers.”
Annual report 2024A · The company itself
Chains in: Ageing population strengthens, GLP-1 and obesity treatment mixed effect
Drug approvals
Regulation
DriverMixed impact: mixed
“The financial success of the Group requires obtaining marketing authorization and achieving an acceptable reimbursement price for its drugs.”
Annual report 2024A · The company itself
DriverMixed impact: mixed
“The Group will need approvals from the FDA to market its products in the US, and from the European Medicines Agency (EMA) to market its products in Europe, as well as equivalent regulatory authorities in other worldwide jurisdictions to commercialize in those regions.”
Annual report 2024A · The company itself
Chains out: this strengthens Biotech and drug development
Patent expiry and generic competition
Regulation
DriverNegative impact: weakens
“The success of the Company will highly depend on the Company’s ability to obtain and maintain patent protection for its products, methods, processes and other technologies, to preserve trade secrets, to prevent third parties from infringing proprietary rights of the Company and to operate without infringing the proprietary rights of third parties. To date, the Company holds certain exclusive patent rights in major markets. The patent rights are limited in time.”
Annual report 2024A · The company itself
Chains out: this weakens Biotech and drug development
US drug pricing policy
Regulation
DriverMixed impact: mixed
“The financial success of the Group requires obtaining marketing authorization and achieving an acceptable reimbursement price for its drugs.”
Annual report 2024A · The company itself
Chains out: this mixed effect Biotech and drug development, weakens GLP-1 and obesity treatment
Labour regulation
Regulation
InputNegative impact: weakens
“PROTECTION OF HUMAN AND LABOR RIGHTS We are committed to the protection of human and labor rights in all our operational endeavors. We recognize the universal and fundamental nature of human rights and align all our operations with the Universal convention on Human Rights and conventions of the International Labor Organization (ILO).”
Annual report 2024A · The company itself
InputNegative impact: weakens
“We have implemented actions related to the 2022 Norwegian Transparency Act, which includes requirements related to performing due diligence, and working on fundamental human rights and decent working conditions. This is in line with our efforts to be a responsible actor, focusing on a responsible supply chain.”
Annual report 2024A · The company itself
Interest rates
Macro
DriverMixed impact: mixed
“The Group’s interest rate risk is; therefore, in the rate of return of its cash on hand. Bank deposits and money market funds are exposed to market fluctuations in interest rates, which affect the financial income and the return on cash.”
Annual report 2024A · The company itself
Chains in: Public debt and fiscal policy strengthens, Inflation strengthens
Chains out: this weakens Construction, weakens Real estate, weakens Wind power, weakens Housing market, weakens Office and commercial property, weakens Residential rental, weakens Residential construction
Labour and wages
Raw materials and inputs
DriverPositive impact: strengthens
“Our employees are at the core of BerGenBio’s growth story. We aim to engender an organizational culture which appeals to employees with varied talent and experience.”
Annual report 2024A · The company itself
Cybersecurity (products and services)
Technology
DriverNegative impact: weakens
“Ensuring the confidentiality and security of our patient’s personal information is of paramount importance to us. In 2024 there were no incidents or claims of data breaches reported.”
Annual report 2024A · The company itself
Chains in: Cyber attacks and IT security risk strengthens
Chains out: this strengthens Digitalisation
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | 0 bn NOK |
| Revenue growth vs. the year before, same method | 139.5 % |
| EBITDA reported by the company | N/A |
| Net debt debt incl. leasing minus cash | N/A |
| Diluted EPS per share | -3.95 NOK |
Source: annual report (ESEF) A. See the report
Criteria
| Profit | ✗ |
| Growing | ✓ |
| Healthy balance sheet | N/A |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.
Figures are in the report's currency (NOK), not converted to DKK. Quotes are shown as the company's own words in the report's original language.